B. Riley Financial Inc. bought a new position in shares of Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 4,600 shares of the biopharmaceutical company’s stock, valued at approximately $213,000.
Other hedge funds have also bought and sold shares of the company. SG Americas Securities LLC bought a new position in Ultragenyx Pharmaceutical during the third quarter worth about $156,000. Ameritas Investment Partners Inc. lifted its holdings in Ultragenyx Pharmaceutical by 7.7% during the second quarter. Ameritas Investment Partners Inc. now owns 3,474 shares of the biopharmaceutical company’s stock worth $216,000 after acquiring an additional 248 shares in the last quarter. Fox Run Management L.L.C. bought a new position in Ultragenyx Pharmaceutical during the third quarter worth about $213,000. Aperio Group LLC bought a new position in Ultragenyx Pharmaceutical during the fourth quarter worth about $254,000. Finally, Cubist Systematic Strategies LLC lifted its holdings in Ultragenyx Pharmaceutical by 83.7% during the second quarter. Cubist Systematic Strategies LLC now owns 5,570 shares of the biopharmaceutical company’s stock worth $346,000 after acquiring an additional 2,538 shares in the last quarter. Hedge funds and other institutional investors own 85.01% of the company’s stock.
Shares of Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) opened at $47.86 on Friday. The stock has a market capitalization of $2,363.72, a PE ratio of -6.73 and a beta of 1.89. Ultragenyx Pharmaceutical Inc has a 12-month low of $41.67 and a 12-month high of $91.35.
Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its earnings results on Tuesday, February 20th. The biopharmaceutical company reported ($2.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.00) by ($0.27). The company had revenue of $2.41 million during the quarter, compared to analyst estimates of $0.75 million. During the same quarter in the prior year, the company posted ($1.75) earnings per share. equities research analysts predict that Ultragenyx Pharmaceutical Inc will post -6.2 earnings per share for the current fiscal year.
Several research firms have weighed in on RARE. BidaskClub lowered Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a report on Friday, February 9th. Canaccord Genuity set a $80.00 target price on Ultragenyx Pharmaceutical and gave the stock a “buy” rating in a report on Thursday, November 16th. Robert W. Baird cut their price target on Ultragenyx Pharmaceutical from $85.00 to $80.00 and set an “outperform” rating on the stock in a report on Friday, November 3rd. Zacks Investment Research lowered Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a report on Tuesday, January 30th. Finally, Credit Suisse Group initiated coverage on Ultragenyx Pharmaceutical in a report on Wednesday, January 17th. They issued an “outperform” rating and a $67.00 price target on the stock. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and thirteen have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $69.53.
TRADEMARK VIOLATION NOTICE: “B. Riley Financial Inc. Acquires Shares of 4,600 Ultragenyx Pharmaceutical Inc (RARE)” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another site, it was copied illegally and reposted in violation of US & international copyright law. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2018/02/24/b-riley-financial-inc-acquires-shares-of-4600-ultragenyx-pharmaceutical-inc-rare.html.
About Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.
Want to see what other hedge funds are holding RARE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ultragenyx Pharmaceutical Inc (NASDAQ:RARE).
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.